Patents by Inventor Varavani Dwarki
Varavani Dwarki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7462592Abstract: This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.Type: GrantFiled: October 22, 2002Date of Patent: December 9, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Ronald N. Zuckermann, Nathalie Dubois-Stringfellow, Varavani Dwarki, Michael A. Innis, John E. Murphy, Fred E. Cohen, Tetsuo Uno
-
Publication number: 20080089938Abstract: This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.Type: ApplicationFiled: October 22, 2002Publication date: April 17, 2008Inventors: Ronald Zuckermann, Nathalie Dubois-Stringfellow, Varavani Dwarki, Michael Innis, John Murphy, Fred Cohen, Tetsuo Uno
-
Publication number: 20030185890Abstract: This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.Type: ApplicationFiled: October 22, 2002Publication date: October 2, 2003Inventors: Ronald N. Zuckermann, Nathalie Dubois-Stringfellow, Varavani Dwarki, Michael A. Innis, John E. Murphy, Fred E. Cohen, Tetsuo Uno
-
Publication number: 20030166284Abstract: Provided are methods for selectively expressing therapeutic molecules, such as secretory proteins, antisense molecules and ribozymes, in the liver. The methods find use in treating hepatic diseases or conditions. The methods also find use in treating any disease or condition in which systemic administration of the therapeutic substance, for example, a secretory protein, is desired. The methods involve administering to a mammalian patient having a need for liver expression of a therapeutic molecule an AAV vector containing a therapeutically effective amount of the therapeutic molecule. Also provided are novel vectors employable in these methods.Type: ApplicationFiled: March 28, 2002Publication date: September 4, 2003Applicant: Chiron CorporationInventors: Arun Srivastava, Selvarangan Ponnazhagan, Robert H. Schloemer, Xu-Shan Wang, Mervin C. Yoder, Shang-Zhen Zhou, Jaime Escobedo, Varavani Dwarki
-
Patent number: 6521225Abstract: The present invention is directed to a recombinant adenovirus vector comprising two inverted terminal repeats (ITRs) each of which comprises a D-sequence having (i) from 5 to 15 native nucleotides and (ii) one or more deletions or substitutions therein.Type: GrantFiled: September 2, 1997Date of Patent: February 18, 2003Assignees: Chiron Corporation, Advanced Research and Technology InstituteInventors: Arun Srivastava, Selvarangan Ponnazhagan, Robert H. Chloemer, Xu-Shan Wang, Mervin C. Yoder, Shang-Zhen Zhou, Jaime Escobedo, Varavani Dwarki
-
Patent number: 6468986Abstract: This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.Type: GrantFiled: July 21, 2000Date of Patent: October 22, 2002Assignee: Chiron CorporationInventors: Ronald N. Zuckermann, Nathalie Dubois-Stringfellow, Varavani Dwarki, Michael A. Innis, John E. Murphy, Fred E. Cohen, Tetsuo Uno
-
Publication number: 20020132336Abstract: The invention provides a method for producing purified replication-defective recombinant AAV virions. The method comprises introducing into a suitable host cell an AAV vector, an AAV helper construct and an adenoplasmid accessory construct into the host cell. The adenoplasmid accessory plasmid is composed adenovirus plasmid DNA unable to be packaged into adenoviral particles because it lacks packaging signal sequence(s) or it contains additional sequences making it too large to package. The host cell is cultured to produce crude rAAV virions and then lysed. The resulting cell lysate is applied to a chromatographic column containing sulfonated cellulose or subjected to cesium chloride equilibrium gradient centrifugation and the purified rAAV virions are recovered.Type: ApplicationFiled: March 15, 2002Publication date: September 19, 2002Applicant: Chiron CorporationInventors: Varavani Dwarki, Martha Baillie Ladner, Jaime Escobedo, Shang-Zhen Zhou
-
Publication number: 20010051611Abstract: Provided are methods for selectively expressing therapeutic molecules, such as secretory proteins, antisense molecules and ribozymes, in the liver. The methods find use in treating hepatic diseases or conditions. The methods also find use in treating any disease or condition in which systemic administration of the therapeutic substance, for example, a secretory protein, is desired. The methods involve administering to a mammalian patient having a need for liver expression of a therapeutic molecule an AAV vector containing a therapeutically effective amount of the therapeutic molecule. Also provided are novel vectors employable in these methods.Type: ApplicationFiled: July 24, 2001Publication date: December 13, 2001Applicant: Chiron Corporation.Inventors: Arun Srivastava, Selvarangan Ponnazhagan, Robert H. Schloemer, Xu-Shan Wang, Mervin C. Yoder, Shang-Zhen Zhou, Jaime Escobedo, Varavani Dwarki
-
Publication number: 20010034054Abstract: The invention provides a method for producing purified replication-defective recombinant AAV virions. The method comprises introducing into a suitable host cell an AAV vector, an AAV helper construct and an adenoplasmid accessory construct into the host cell. The adenoplasmid accessory plasmid is composed adenovirus plasmid DNA unable to be packaged into adenoviral particles because it lacks packaging signal sequence(s) or it contains additional sequences making it too large to package. The host cell is cultured to produce crude rAAV virions and then lysed. The resulting cell lysate is applied to a chromatographic column containing sulfonated cellulose or subjected to cesium chloride equilibrium gradient centrifugation and the purified rAAV virions are recovered.Type: ApplicationFiled: April 24, 2001Publication date: October 25, 2001Inventors: Varavani Dwarki, Martha Baillie Ladner, Jaime Escobedo, Shang-Zhen Zhou
-
Patent number: 6251433Abstract: This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.Type: GrantFiled: August 13, 1997Date of Patent: June 26, 2001Assignee: Chiron CorporationInventors: Ronald N. Zuckermann, Nathalie Dubois-Stringfellow, Varavani Dwarki, Michael A. Innis, John E. Murphy, Fred E. Cohen, Tetsuo Uno
-
Patent number: 6221646Abstract: The invention provides a method for producing purified replication-defective recombinant AAV virions. The method comprises introducing into a suitable host cell an AAV vector, an AAV helper construct and an adenoplasmid accessory construct into the host cell. The adenoplasmid accessory plasmid is composed adenovirus plasmid DNA unable to be packaged into adenoviral particles because it lacks packaging signal sequence(s) or it contains additional sequences making it too large to package. The host cell is cultured to produce crude rAAV virions and then lysed. The resulting cell lysate is applied to a chromatographic column containing sulfonated cellulose or subjected to cesium chloride equilibrium gradient centrifugation and the purified rAAV virions are recovered.Type: GrantFiled: July 31, 1998Date of Patent: April 24, 2001Assignee: Chiron CorporationInventors: Varavani Dwarki, Martha Baillie Ladner, Jaime Escobedo, Shang-Zhen Zhou